Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-CHOP with CNS prophylaxis and scrotal irradiation for primary testicular diffuse large B-cell lymphoma
2009-011789-26Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 2 more in Primary Testicular Diffuse Large B Cell Lymphoma (PT-DLBCL) and testicular lymphoma (PTL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Overall response rate and Safety and feasibility. Started Aug 2009; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
Primary Testicular Diffuse Large B Cell Lymphoma (PT-DLBCL)testicular lymphoma (PTL)
Beyond the preview
Go deeper on 2009-011789-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011789-26.